Strategic Footprint Target regional expansion for human and veterinary probiotics in North America and Canada, leveraging the recent Visbiome Vet GI Care+ launch and NASC Quality Seal to approach clinics, animal hospitals, and pet retailers with proven regulatory and quality credentials.

Product Expansion Position EXE-346 and Visbiome lines as clinically supported, high-potency probiotic solutions for human and animal health, offering channels for clinical trial partnerships, contract manufacturing, and licensed distribution to extend market reach.

Regulatory Credibility Utilize FDA Orphan Drug designation and NASC Quality Seal to differentiate in conversations with pharma distributors, specialty retailers, and veterinary networks seeking compliant, high-standard probiotic products.

Commercial Growth Capitalize on existing revenue range and small-to-medium company profile to pursue B2B partnerships with mid-tier distributors and specialty out-license deals, aligning multiple product SKUs with favorable margin opportunities.

Technology & Data Highlight tech stack foundations and analytics capabilities (e.g., Google Analytics) to offer data-backed marketing and performance insights for partner campaigns, while proposing co-marketing and market access studies to prospective collaborators.